Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer

Joong B. Ahn; Kwang Y. Shim; Hei C. Jeung; Sun Y. Rha; Nae C. Yoo; Nam K. Kim; Jae K. Roh; Jin S. Min; Byung S. Kim; Hyun C. Chung

doi:10.1016/S0304-3835(01)00485-2

Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer

Joong B. Ahn, Kwang Y. Shim, Hei C. Jeung, Sun Y. Rha, Nae C. Yoo, Nam K. Kim, Jae K. Roh, Jin S. Min, Byung S. Kim, Hyun C. Chung

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We investigated the dose-related effect of the 5-fluorouracil (5-FU)/leucovorin regimen on survival in 139 colon cancer patients with Dukes' B2 and C2 stage disease. Chemotherapy consisted of 400 mg/m² of 5-FU and 20 mg/m² of leucovorin injected daily for 5 days in every 4 weeks for a maximum of 12 cycles. The total dose of 5-FU administered per body surface area had a significant effect on the 5-year disease-free survival and 5-year overall survival in stage B2 and C2 colon cancer patients (P=0.0018, P=0.0011). Analysis with reference to the median DSDI demonstrated that there was a significant difference in 5-year survival in Dukes' C2 (P=0.0016), but survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administered per surface area affected the 5-year disease-free survival and 5-year overall survival (P=0.0016, P=0.0007, respectively). It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer.

Original language	English
Pages (from-to)	215-224
Number of pages	10
Journal	Cancer Letters
Volume	167
Issue number	2
DOIs	https://doi.org/10.1016/S0304-3835(01)00485-2
Publication status	Published - 2001 Jun 26

Bibliographical note

Funding Information:
This work was supported by the Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center (CMRC) at Yonsei University.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0304-3835(01)00485-2

Cite this

@article{e154706673754f9fa9fbe1c39dd92b7c,

title = "Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer",

abstract = "We investigated the dose-related effect of the 5-fluorouracil (5-FU)/leucovorin regimen on survival in 139 colon cancer patients with Dukes' B2 and C2 stage disease. Chemotherapy consisted of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin injected daily for 5 days in every 4 weeks for a maximum of 12 cycles. The total dose of 5-FU administered per body surface area had a significant effect on the 5-year disease-free survival and 5-year overall survival in stage B2 and C2 colon cancer patients (P=0.0018, P=0.0011). Analysis with reference to the median DSDI demonstrated that there was a significant difference in 5-year survival in Dukes' C2 (P=0.0016), but survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administered per surface area affected the 5-year disease-free survival and 5-year overall survival (P=0.0016, P=0.0007, respectively). It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer.",

author = "Ahn, {Joong B.} and Shim, {Kwang Y.} and Jeung, {Hei C.} and Rha, {Sun Y.} and Yoo, {Nae C.} and Kim, {Nam K.} and Roh, {Jae K.} and Min, {Jin S.} and Kim, {Byung S.} and Chung, {Hyun C.}",

note = "Funding Information: This work was supported by the Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center (CMRC) at Yonsei University.",

year = "2001",

month = jun,

day = "26",

doi = "10.1016/S0304-3835(01)00485-2",

language = "English",

volume = "167",

pages = "215--224",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer

AU - Ahn, Joong B.

AU - Shim, Kwang Y.

AU - Jeung, Hei C.

AU - Rha, Sun Y.

AU - Yoo, Nae C.

AU - Kim, Nam K.

AU - Roh, Jae K.

AU - Min, Jin S.

AU - Kim, Byung S.

AU - Chung, Hyun C.

N1 - Funding Information: This work was supported by the Korea Science and Engineering Foundation (KOSEF) through the Cancer Metastasis Research Center (CMRC) at Yonsei University.

PY - 2001/6/26

Y1 - 2001/6/26

N2 - We investigated the dose-related effect of the 5-fluorouracil (5-FU)/leucovorin regimen on survival in 139 colon cancer patients with Dukes' B2 and C2 stage disease. Chemotherapy consisted of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin injected daily for 5 days in every 4 weeks for a maximum of 12 cycles. The total dose of 5-FU administered per body surface area had a significant effect on the 5-year disease-free survival and 5-year overall survival in stage B2 and C2 colon cancer patients (P=0.0018, P=0.0011). Analysis with reference to the median DSDI demonstrated that there was a significant difference in 5-year survival in Dukes' C2 (P=0.0016), but survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administered per surface area affected the 5-year disease-free survival and 5-year overall survival (P=0.0016, P=0.0007, respectively). It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer.

AB - We investigated the dose-related effect of the 5-fluorouracil (5-FU)/leucovorin regimen on survival in 139 colon cancer patients with Dukes' B2 and C2 stage disease. Chemotherapy consisted of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin injected daily for 5 days in every 4 weeks for a maximum of 12 cycles. The total dose of 5-FU administered per body surface area had a significant effect on the 5-year disease-free survival and 5-year overall survival in stage B2 and C2 colon cancer patients (P=0.0018, P=0.0011). Analysis with reference to the median DSDI demonstrated that there was a significant difference in 5-year survival in Dukes' C2 (P=0.0016), but survival was not affected by the dose intensity. Multivariate analysis demonstrated that only the total dose of 5-FU administered per surface area affected the 5-year disease-free survival and 5-year overall survival (P=0.0016, P=0.0007, respectively). It can be concluded that the total dose of 5-FU administered is important in planned dosage schedule of adjuvant chemotherapy in colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035954238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035954238&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00485-2

DO - 10.1016/S0304-3835(01)00485-2

M3 - Article

C2 - 11369143

AN - SCOPUS:0035954238

SN - 0304-3835

VL - 167

SP - 215

EP - 224

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this